Genmab — September 2025
-
Sådan har de danske biotech aktier performet den seneste måned https://proinvestor.com/investornyt/1363579/sadan-har-de-danske-biotech-aktier-performet-den-seneste-maned
-
Brud opad gennem loftet af faldende trendkanal på mellemlang sigt, med stærk prisstigning siden rektangel-formationens brud ved 1506 DKK (mål på 1650 og 1754 opfyldt). RSI over 70 viser stærk positiv momentum, stigende optimisme og pris over kritiske støtteniveauer. Analytikere ser 31,68% upside-potentiale.
-
Nu kunne jeg godt tænke mig at @Stockbull kom på banen. - Han har om nogen ramt aktien i uptrends tider. Og her skulle vi jo befinde os nu...
-
Guggenheim analyst Michael Schmidt upgraded Genmab (GMAB) to Buy from Neutral with a $43 price target, citing increased conviction in Epkinly’s outlook https://www.tipranks.com/news/the-fly/genmab-upgraded-to-buy-at-guggenheim-on-royalty-revenue-upside-potential-thefly
-
Genmab: Major Shareholder Announcement https://proinvestor.com/investornyt/1364289/major-shareholder-announcement
-
Genmab får købsanbefaling fra amerikansk børshus: Ser potentiale på 50 pct. https://proinvestor.com/investornyt/1364272/genmab-far-kobsanbefaling-fra-amerikansk-borshus-ser-potentiale-pa-50-pct
-
Genmab får ny storaktionær https://proinvestor.com/investornyt/1364304/genmab-far-ny-storaktionaer
-
Orbis was set up in 1989. Our founder Allan Gray believed that a fundamental, contrarian long-term approach offered great potential. If he applied it successfully, he could help people grow their money meaningfully over time.
Until 2015, our Funds were only available to institutions, like pension funds, with millions to invest. But we wanted to make investing in funds simpler and more accessible for everyone.
-
Læs mere om den nye storaktionær: https://www.orbis.com/uk/individual/about-us/about-us
-
Børsmeddelelsen er kommet i dag.
-
Ok Bikube.
-
New Novartis data further support benefits of Kesimpta
in relapsing MS following switch from oral disease modifying therapies https://www.prnewswire.com/news-releases/new-novartis-data-further-support-benefits-of-kesimpta-in-relapsing-ms-following-switch-from-oral-disease-modifying-therapies-302565142.html -
Johnson & Johnson at Bernstein Forum: Strategic Growth and Innovation https://www.investing.com/news/transcripts/johnson--johnson-at-bernstein-forum-strategic-growth-and-innovation-93CH-4253958
men lidt stoppen op er almindeligt.
Du plejer at ramme den temmelig godt, kan man roligt sige.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind